Sell V, et al. - Researchers conducted this substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) that investigated the efficacy of photodynamic diagnosis and 6 weekly optimized mitomycin C instillations in pTa bladder cancer with high risk for recurrence, in order to study the symptoms and delays in the clinical pathway of bladder cancer. This analysis comprised 131 patients with primary bladder cancer and their complete data. Outcomes revealed a short patient-derived delay (7 days); however, main delays in diagnosis of bladder cancer take place in specialized medical care. The entire diagnostic pathway had median time of 78 days. They noted prolonged pre-consultation delays among never smokers and patients presenting with symptoms other than hematuria and patients referred from private outpatient clinics. However, no differences in delays considering age and gender were identified.